

**ASX ANNOUNCEMENT:** June 1, 2017

## **Immuron Secures R&D Cash Advance Loan Funding**

- Immuron's major shareholder Grandlodge to provide another R&D refund a cash advance loan as in previous years
- Loan will ensure Immuron is funded through until after the release of the NASH Clinical Trial Interim Analysis results

## Immuron Secures R&D Cash Advance Loan Funding

**Melbourne, Australia, June 1, 2017:** Australian biopharmaceutical Company, Immuron Limited (ASX: IMC), is today pleased to announce that the Company has secured a AUD\$1.5M loan in the form of a cash advance against its anticipated FY2017 R&D Tax Concession Refund from the Company's major shareholder Grandlodge.

This cash advance loan will ensure the Company has sufficient funding through until after the release of the NASH clinical trial interim analysis results which will mark a milestone and inflection point for the Company which is to occur during early July 2017.

Immuron Chairman Dr Roger Aston commented;

*"Following the Board's decision this morning to put the interests of its shareholders at the forefront of any determination to progress with the NASDAQ listing at this time, it is a fantastic sign of solidarity to know that our major shareholder is willing to stand behind the Board's decision and support the Company through the next period to reach our pending significant inflection point"*

The specific details of the Grandlodge loan are confidential, but the loan terms of the loan are such that the loan is deemed to be arms-length at commercially applicable market rates.

-- END --

### COMPANY CONTACT:

**Thomas Liquard**

Chief Executive Officer

Ph: +61 (0)3 9824 5254

thomasliquard@immuron.com

### IMMURON INVESTOR RELATIONS:

**Peter Taylor**

NWR Communications

Ph: +61 (0)4 1203 6231

peter@nwrcommunications.com.au

### ABOUT IMMURON:

Immuron Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers' diarrhea whilst its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: <http://www.immuron.com>

### FORWARD-LOOKING STATEMENTS:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron

---

will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.